Zevra Therapeutics, Inc. (ZVRA) Total liabilities 2018–2025
Zevra Therapeutics, Inc. (ZVRA) total liabilities at each fiscal year-end, per SEC filings.
$130.1MFY2025 · since FY2018: $93.3M → $130.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $130.1M | -6.1% |
| FY2024 | $138.5M | +25.3% |
| FY2023 | $110.5M | +174.6% |
| FY2022 | $40.2M | +590.7% |
| FY2021 | $5.8M | -92.5% |
| FY2020 | $77.6M | -8.6% |
| FY2019 | $85.0M | -8.9% |
| FY2018 | $93.3M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ZVRA financial trends
ZVRA RevenueZVRA Net incomeZVRA Net marginZVRA Gross profitZVRA Gross marginZVRA Operating incomeZVRA Operating marginZVRA Operating cash flowZVRA Free cash flowZVRA Capital expendituresZVRA Return on equityZVRA Stock buybacksZVRA Dividends paidZVRA Total assetsZVRA Shareholders’ equityZVRA overview →